tbuckley/cabot-search huggingface dataset:
Correlation of Clinical Features with the Mutational Status of GM-CSF Signaling Pathway-Related Genes in Children with Juvenile Myelomonocytic Leukemia
Authors: Nao Yoshida, Hiroshi Yagasaki, Ayami Yoshimi, Yoshiyuki Takahashi, Yinyan Xu, Makito Tanaka, Nobuhiro Watanabe, Kimikazu Matsumoto, Koji Kato, Junichi Ueyama, Hiroko Inada, Hiroaki Goto, Miharu Yabe, Junichi Mimaya, Akira Kikuchi, Atsushi Manabe, Seiji Kojima
Journal: Blood (2007)
Lymphocyte Function and Molecular Mechanisms of Enhanced Immune Reconstitution Following Sex Steroid Ablation and Hemopoietic Stem Cell Transplantation (HSCT).
Authors: Gabrielle L. Goldberg, Önder Alpdogan, Stephanie J. Muriglan, Maree Hammett, Morag K. Milton, Jeffrey M. Eng, Vanessa M. Hubbard, Adam Kochman, Lucy M. Willis, Andrew S. Greenberg, Kartono H. Tjoe, Jayne S. Sutherland, Ann Chidgey, Richard L. Boyd, Marcel R.M. van den Brink
Journal: Blood (2004)
310P Oral leukoplakia in women treated with long-term pegylated liposomal doxorubicin
Authors: H. Nomura, M. Nagashima, M. Matoda, S. Okamoto, H. Kanao, K. Kato, K. Omatsu, Y. Sugiyama, K. Utsugi, N. Takeshima
Journal: Annals of Oncology (2016)
Prognostic impact of KRAS mutation in metastatic (met) pancreatic cancer patients (pts)
Authors: H. Verdaguer, T. Sauri, F. Ruiz, A. Vivancos, P. Nuciforo, J. Capdevila, E. Elez, M. Alsina, G. Argiles Martinez, C. Hierro, J. Grasselli, I. Matos, J. Tabernero, R. Dienstmann, T. Macarulla
Journal: Annals of Oncology (2016)
Formation of FVIIa-Antithrombin Complexes After Administration of rFVIIa to Hemophilia Patients.
Authors: Mirella Ezban, Erika Martin, John Christian Barrett, Janice Kuhn, Mindy Nolte, Hermann Pelzer, Henrik Agerso, Lars Christian Petersen, Ulla Hedner, Marcus E. Carr, Donald Brophy
Journal: Blood (2009)
Evaluation of an interactive portal for breast cancer survivors: Use, satisfaction, and preliminary effects.
Authors: Wilma Kuijpers, Wim G Groen, Hester SA Oldenburg, Michel W.J.M. Wouters, Neil K Aaronson, Wim H van Harten
Journal: Journal of Clinical Oncology (2016)

200 Background: MijnAVL is an interactive portal that includes patient education, an overview of appointments, access to the electronic medical record (EMR), patient-reported outcomes plus feedback and physical activity support. The aim of this feasibility study was to evaluate use, satisfaction and preliminary effects among breast cancer survivors. Methods: We included women currently or recently treated for breast cancer with curative intent. At baseline, they completed a questionnaire on sociodemographics, expectations of MijnAVL and three effect measures: patient activation (PAM), quality of life (SF-36), and physical activity (IPAQ). MijnAVL could be used noncommittally for 4 months. Log data were collected retrospectively and participants completed questions on satisfaction and effect measures. This process was conducted twice, to be able to improve MijnAVL iteratively. Results: We included 92 women (mean age 49.5 years, 59% on-treatment). Mean number of logins was 8.7 and mean duration 13.1 minutes. Overview of appointments (80% of participants) and access to the EMR (90%) were most frequently used and most appreciated. Website user satisfaction was rated 3.8 on a 1-5 scale on average and participants were primarily positive about the accessibility of information. We did not find an effect on the PAM. For the SF-36, we found significant improvements on the role functioning – emotional (65.3 to 78.5, p&lt; .01), mental health (69.8 to 76.5, p&lt; .01) and social functioning (71.2 to 80.5, p&lt; .01) domains. Median vigorous physical activity significantly increased from 0 to 360 MET-minutes per week (p&lt; .05); levels of walking and moderate physical activity did not change significantly over time. These effects were not related to the intensity of use of MijnAVL. Conclusions: This study showed that user experiences were positive and that exposure to MijnAVL resulted in improvements on three quality of life domains and vigorous physical activity. More tailored, interactive features might be needed to substantially change empowerment, quality of life and physical activity. Research with a controlled design and possibly a more sensitive measure for patient empowerment are needed to substantiate our findings.
Use of the in Vitro Immortalization Assay to Quantify the Impact of Integration Spectrum and Vector Design on Insertional Mutagenesis
Authors: Ute Modlich, Julia Sürth, Daniela Zychlinski, Johann Meyer, Christian Brendel, Manuel Grez, Paritha Arumugam, Punam Malik, Elke Grassman, Axel Schambach, Christopher Baum
Journal: Blood (2011)
Hematology patient reported symptom screen to assess quality of life for AL amyloidosis
Authors: Rahma Warsame, Shaji K. Kumar, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, Nelson Leung, David Dingli, John A. Lust, Yi Lin, Stephen Russell, Prashant Kapoor, Ronald S. Go, Taxiarchis Kourelis, Wilson Gonsalves, Steven R. Zeldenrust, Robert A. Kyle, S. Vincent Rajkumar, Tyler Zemla, Jeffrey Sloan, Angela Dispenzieri
Journal: American Journal of Hematology (2017)

Patients with light chain amyloidosis (AL) often have delayed diagnosis and present with significant symptomatology; this may result in decreased quality of life (QOL). We prospectively employ a "Hematology Patient Reported Symptom Screen" (HPRSS), which is three questions about fatigue, pain, and QOL, scored 0-10. The aim of this study is to better understand QOL and determine if HPRSS parameters predict for clinical outcomes. From 2009 to 2014, 302 newly diagnosed AL patients were included. Baseline median scores [interquartile range] for fatigue, pain, and QOL were 6 [3,7], 2 [0,5], 5 [3,8], respectively. Median overall survival was 53 months, with 102 (34%) deaths in the first year. There were significant differences in baseline HPRSS between those that lived longer than one year and early death patients in the domains of fatigue (5 [IQR 3, 7] vs. 7 [IQR 5, 8], P < 0.0001) and QOL (6 [IQR 4, 8] vs. 5 [IQR 3, 7], P = 0.006). On univariate analysis fatigue, QOL, physician-reported performance status, autologous stem cell transplant (ASCT), and Mayo stage were prognostic for survival. On multivariate analysis Mayo stage, ASCT, and baseline fatigue remained independently prognostic. When analyses were restricted to the 125 patients with HPRSS measurements at 12 months, we found that over time QOL scores improved significantly 6 [IQR 3.5, 8] → 7 [IQR 5, 8] (P = 0.01). Asking AL patients to rate their fatigue and QOL has predictive value. Baseline patient reported fatigue is an independent prognostic factor for survival. Survival at one year was associated with significant improvement in QOL.
Dynamic contrast enhanced MRI (DCE-MRI) as a potential predictor of clinical response in patients with inflammatory breast cancer (IBC)
Authors: A. Doshi, S. B. Wedam, D. M. Thomasson, R. M. Garcia-Eulate, B. J. Wise, J. Yao, S. M. Steinberg, D. J. Liewehr, P. Choyke, S. M. Swain
Journal: Journal of Clinical Oncology (2005)

584 Introduction: We compared three models of DCE-MRI analysis to determine which parameter or combination would best predict clinical response after bevacizumab (BV) alone or BV and chemotherapy (chemo). Methods: 21 patients (pts) with untreated IBC received BV for cycle (C) 1 (15 mg/kg on day 1) followed by 6 C of BV (15mg/kg) with doxorubicin (50mg/m2) and docetaxel (75 mg/m2) every 3 weeks. DCE-MRIs were obtained at baseline (BL), after C1, 4, and 7. Regions of Interest (ROIs) were drawn around the most enhanced area, excluding necrotic areas. Data were analyzed using: 1) Heuristic model: measurement of wash-in and -out slopes and area under the curve (AUC) for 90, 180, 270 and 360 seconds after injection; 2) Brix model: Amplitude and kep; 3) General Kinetic Model (GKM): Ktrans and kep. Absolute values and relative changes at BL, C1, C4, and C7 were compared by response. Multiple comparisons necessitated p<0.01 for significance. Results: 20 pts assessed: 13 partial response (PR), 7 stable or progressive disease (SD/PD). The median relative changes from BL to C1 (after BV alone) for Brix kep were −0.301 for PR and −0.006 for SD/PD (p=0.34), for GKM kep were −0.325 for PR and −0.166 for SD/PD (p=0.50), and for Heuristic slope wash-out were −0.940 for PR and 1.425 for SD/PD (p=0.17). The median relative changes from BL to C4 (after BV and chemo) for Heuristic slope wash-in was −0.732 for PR and −0.457 for SD/PD (p=0.004) and for AUC 90 was −0.675 and −0.364 (p=0.007). Absolute values for slope wash-out after C1 (BV alone) were 0.01 for PR and 0.04 for SD/PD (p=0.032). Other parameters and combinations evaluated were not significant. Conclusions: A significant difference between PR and SD/PD from BL to C4 was seen in the parameters, Heuristic slope wash-in and AUC90. Slope wash-out at C1 exhibited a trend toward a difference according to clinical response. Brix kep and GKM kep did not discriminate between PR and SD/PD after BV alone, however there were smaller relative changes in patients with SD/PD compared to those with PR. Future work will investigate the inclusion of necrotic areas to evaluate whether this improves the ability of DCE-MRI to predict clinical response with any of the three models. No significant financial relationships to disclose.
Cord Blood-Derived T Cells Can Be Genetically Engineered to Be B-Lineage All-Specific: Towards Adoptive Immunotherapy after Umbilical Cord Blood Transplantation.
Authors: Laurence J.N. Cooper, Lisa Marie Serrano, Zaid Al-Kadhimi, Simon Olivares, Sergio Gonzalez, Timothy Pfeiffer, Joseph Rosenthal, Steven J. Forman, Michael C. Jensen
Journal: Blood (2004)
A new two-step algorithm for the treatment of COPD
Authors: Marc Miravitlles, Antonio Anzueto
Journal: European Respiratory Journal (2017)

The pharmacological treatment of chronic obstructive pulmonary disease (COPD) is quite uniformly based on long-acting bronchodilators (LABD), either a long-acting muscarinic antagonist (LAMA) or a long-acting β-agonist (LABA), and inhaled corticosteroids (ICS). Moreover, most patients are eventually treated with a combination of all three (LAMA/LABA/ICS or "triple therapy") irrespective of their severity and level of risk. Furthermore, a large proportion of patients receive triple therapy as the initial treatment [1]. We propose a new simple treatment algorithm based on the severity of symptoms and phenotypes or treatable traits (figure 1). Treatment of COPD can be simplified with a two-step algorithm according to severity and phenotype <http://ow.ly/iJUN306DEHU>
Gemtuzumab-Ozogamicin as Post-Consolidation Therapy In Elderly Patients with Acute Myeloid Leukemia: a Pilot Study
Authors: Capelli Debora, Giorgia Mancini, Martina Chiarucci, Francesco Saraceni, Antonella Poloni, Silvia Trappolini, Benedetta Costantini, Mauro Montanari, Guido Gini, Ilaria Scortechini, Pietro Leoni, Attilio Olivieri
Journal: Blood (2010)
Identification of Unique Antigenic Determinants in the Amino Terminus of IA-2 (ICA512) in Childhood and Adult Autoimmune Diabetes: New Biomarker Development
Authors: Maria Acevedo-Calado, Eddie A. James, Michael P. Morran, Susan L. Pietropaolo, Qin Ouyang, David Arribas-Layton, Marco Songini, Marco Liguori, Anna Casu, Richard J. Auchus, Shuai Huang, Liping Yu, Aaron Michels, Roberto Gianani, Massimo Pietropaolo
Journal: Diabetes Care (2017)

OBJECTIVE The characterization of diverse subtypes of diabetes is a dynamic field of clinical research and an active area of discussion. The objective of this study was to identify new antigenic determinants in the neuroendocrine autoantigen IA-2 (ICA512) and assess whether circulating autoantibodies directed to new IA-2 epitopes identify autoimmune diabetes in young and adult populations with diabetes. RESEARCH DESIGN AND METHODS Clinically diagnosed patients with type 2 diabetes (n = 258; diabetes duration: 0.01–31 years) were evaluated using a new biomarker detecting autoantibodies directed to the extracellular domain of the neuroendocrine autoantigen IA-2 (IA-2ec). The proportion of IA-2ec autoantibodies was also evaluated in newly diagnosed patients with type 1 diabetes (n = 150; diabetes duration: 0.04–0.49 years). In addition, IA-2 (intracellular domain), GAD65, and zinc transporter 8 autoantibodies were assayed. RESULTS IA-2ec autoantibodies were detected in patients with type 1 diabetes and, surprisingly, in 5% of patients with type 2 diabetes without serologic responses to other IA-2 antigenic epitopes or other islet autoantigens. We also assessed the ability of IA-2ec–derived peptides to elicit CD4+ T-cell responses by stimulating peripheral blood mononuclear cells from patients with type 1 diabetes (n = 18) and HLA-matched healthy subjects (n = 13) with peptides and staining with the peptide/DQ8-specific tetramers, observing disease-associated responses to previously unreported epitopes within IA-2ec. CONCLUSIONS We developed a new antibody biomarker identifying novel antigenic determinants within the N terminus of IA-2. IA-2ec autoantibodies can be detected in patients with type 1 diabetes and in a subgroup of adult autoimmune patients with type 2 diabetes phenotype negative for conventional islet autoantibody testing. These observations suggest that islet autoimmunity may be more common in clinically diagnosed type 2 diabetes than previously observed.
Palliative care and hospice use among melanoma patients treated with immunotherapy.
Authors: Ryan David Nipp, Allison Shayna Betof, Krista M. Rubin, Shauna M. Blackmon, Keith Flaherty, Donald P. Lawrence, Ryan J. Sullivan
Journal: Journal of Clinical Oncology (2015)

116 Background: PD-1/PD-L1 inhibitors (PD-1/PD-L1i) have revolutionized the treatment of patients with metastatic melanoma. However, little is known about the supportive care needs and use of palliative care (PC) services in these patients. We sought to assess rates and correlates of PC consultation and hospice use among melanoma patients treated with PD-1/PD-L1i. Methods: We retrospectively collected data on all patients with melanoma treated with PD-1/PD-L1i at the Massachusetts General Hospital (MGH) from May 2009 to March 2015. We determined rates of PC consultation and hospice use in this sample. We used logistic regression with purposeful selection of covariates to identify correlates of PC consultation. Results: Of 122 patients treated at MGH (mean age = 61.2 years), most were married (n = 91, 75%) and college educated (n = 66, 54%). Overall, 83 patients (68%) experienced autoimmune toxicities, 22 (18%) had liver metastases, 87 (71%) had cancer progression and 44 (36%) died during our study period. We found that 36 patients (30%) received PC consultation during their treatment course; 9 (25%) of these occurred over 6 months prior to the patients’ death, and 11 (31%) in their last month of life. Among the patients who died, 36 (82%) received hospice services, and 11 (31%) enrolled in hospice during their last week of life. In our regression model, younger age, having cancer progression and presence of liver metastases correlated with increased likelihood of receiving PC consultation. Conclusions: Melanoma patients treated with immunotherapy often receive PC and hospice services late in their treatment course. These data underscore the difficulty understanding when to involve hospice and PC for these patients, and highlight the need for further PC research in this patient population. Additionally, younger age, presence of cancer progression and liver metastases were associated with receiving PC consultation, thus suggesting the need for integrated PC services among certain subpopulations of these patients. [Table: see text]
Aryl hydrocarbon receptor in airway epithelium exacerbates cockroach allergen-induced asthma through autophagy
Authors: Yilin Zhao, Xiaoyan Luo, Lipeng Qiu, Danh C. Do, Xia Ke, Eric Zaccone, Bradley J. Undem, Peisong Gao
Journal: Journal of Allergy and Clinical Immunology (2017)
The Effect Of SLC9A3 On Esophageal Epithelium In Eosinophilic Esophagitis (EoE)
Authors: Chang Zeng, David Wu, Simone Vanoni, Taeko Noah, Eitaro Aihara, Artem Barski, Andrey Kartashov, Mark Rochman, Joseph Sherrill, Marc E. Rothenberg, Simon P. Hogan
Journal: Journal of Allergy and Clinical Immunology (2017)
Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer.
Authors: Jin-Wan Wang, Yihebali Chi, Zhao-xu Zheng, Tao Qu, Ai-Ping Zhou, Lin Yang, Wen-chang Jiang, Shu-zhen Shi, Yong-kun Sun, Yan Song, Su-yi Kang
Journal: Journal of Clinical Oncology (2012)

e14668 Background: Nimotuzumab, a humanized IgG1 anti-EGFR monoclonal antibody, has demonstrated efficacy associated with an absence of severe skin toxicity in many phase I/II cancer trials. Methods: This is a single-center, parallel assignment and open-label study randomized to receive a infusion Cisplatin (30mg/m 2 /d, on day 1 and 2) and oral S-1 (80mg/m 2 /d, twice daily on day 1-14) every 3 weeks, either alone or together with Nimotuzumab (200 mg as a infusion on day 1, 8 and 15) (CS or NCS) as 1st line in patients with advanced or metastatic gastric cancer. The observation points were ORR, TTP, PFS, 1-year survival rates and safety. Results: 62 patients, 43 men and 19 women, median age 57 years (22-76 years), on good performance status (ECOG PS 0-2, one prior regimen) were treated with NCS (n = 31) or CS (n = 31). Up to 2012-01-16, 57 patients (NCS 30 cases compared with CS 27 cases) have undergone efficacy assessment. The objective response rate (ORR: PR 15) was 50% (15/30) in NCS group compared with (ORR: pCR 2+ PR 15) 63.0% (17/27) in CS group. Disease control rate was 96.7% and 96.3%, respectively. Until the same day, 36 patients have achieved progression in both groups (NCS 15: CS 11), median TTP was 5 months in NCS group compared with 3 months in CS group, and average TTP was 4.9 months and 4 months, respectively. The incidence of adverse events was similar between both groups. Adverse events included grade 3/4 hypo-hemoglobin 13.33%/7.41%, grade 3/4 thrombocytopenia 3.33%/0 and grade 3/4 neutropenia 3.33%/0. One patient experienced grade 3/4 digestive side effects 3.33%/0. Conclusions: The results have demonstrated benefit in TTP improvement. Further investigation is ongoing.
Impact of stress on diabetes self-management in cancer survivors.
Authors: Janey James, Natalie Coppa, Alexandra Rosenberg, Juan P. Wisnivesky, Jenny J Lin
Journal: Journal of Clinical Oncology (2016)

11 Background: Few studies have evaluated the impact of stress on diabetes self- management among cancer survivors. We undertook this study to assess factors associated medication adherence and diabetes self-management in a cohort of diabetic patients with recently-diagnosed early-stage cancer. Methods: We recruited diabetes patients recently diagnosed with early-stage breast, prostate, lung or colorectal cancer on at least one oral hypoglycemic agent and used the Impact of Event Scale (IES) to assess the subjective distress caused by cancer. The 15-item IES consists of 2 subscales assessing avoidant and intrusive feelings about cancer. We measured medication adherence using the 8-item Morisky Medication Adherence Scale, and diabetes self-management behaviors were evaluated using the Summary of Diabetes Self-Care Activities. Participants were surveyed at baseline and after 3 months. Descriptive and univariate analyses were used to assess baseline factors associated with diabetes self-management at 3 months. Results: Of the 36 participants recruited to date, 20 (56%) were male. At baseline, 70% reported adherence to their diabetes medications which dropped to 63% at 3 months. There were no gender differences between IES scores at baseline; however, at 3 months women were more stressed (p = 0.02) and had more intrusive thoughts (p = 0.005) about cancer. Higher baseline total IES scores were associated with lack of a general healthy diet (p = 0.01). Patients who had trouble falling asleep from thoughts about cancer felt more hassled sticking to their diabetes medication treatment at 3 months (p = 0.02). Those who had dreams about cancer (p = 0.007) and those who tried to stay away from reminders about cancer (p = 0.04) were more likely to forget their diabetes medications when travelling. Lastly, patients who felt that the cancer wasn’t real were more likely to have difficulty remembering to take medications (p = 0.03). Conclusions: Cancer survivors with comorbid diabetes who have higher stress are less likely to follow a healthy diet and more likely to report trouble with taking their diabetes medications. Providers should be aware of the impact of stress caused by cancer to better support diabetes self-management among early cancer survivors.
Abstract 197: Selective Destruction of Adrenergic Cells in Mice Leads to Severe Left-ventricular Dysfunction at Rest With Apparent Stress-induced Recovery
Authors: Aaron P Owji, Candice N Baker, Jeffrey Jacob, Steven N Ebert
Journal: Circulation Research (2015)

The catecholamines epinephrine and norepinephrine play critical roles in the maintenance of cardiovascular function. Phenylethanolamine-N-methyltransferase (Pnmt) catalyzes the conversion of norepinephrine to epinephrine and serves as a marker for adrenergic cells. We have previously shown that the selective destruction of Pnmt+ cells in the mouse produces severe left-ventricular dysfunction under anesthesia and that epinephrine deficiency alone does not recapitulate the phenotype. Here, we test the hypothesis that Pnmt+ cells are key modulators of the stress response to immobilization. Using a suicide reporter mouse model to ablate Pnmt+ cells (Pnmt-Cre/DTA), we achieve greater than 50% Pnmt+ cell reduction in the adrenal medulla and 97% reduction in Pnmt transcript. Remarkably, Pnmt+ cell destruction does not markedly diminish the cardiovascular response to restraint stress. At one hour of immobilization, heart rate and ejection fraction showed a similar increase in response to restraint in both groups, despite apparent heart failure in Pnmt-Cre/DTA mice at rest (Figure 1). Here, we show that, while Pnmt+ cells are required for the maintenance of basal cardiovascular function, loss of these cells does not diminish the cardiovascular response to restraint stress. These results suggest that left ventricular cardiac muscle has the capacity to respond to stress despite hypokinetic and poor ventricular function at baseline.